Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
--------
Question: According to the story, brand-name aromatase inhibitors cost between $340 and $420 a month, but the story also points out that lower-costing, generic versions are available in the U.S. It would have been useful had the story also provided cost information for the other preventive drug options, tamoxifen and raloxifene. A particular strength of this story is its presentation of data. Dr. Winer, an independent source included in the story, translates a 65% risk reduction to mean that exemestane may reduce a woman's risk of developing breast cancer from 3% to 1%. Not only does the story provide absolute risk, but it also presents the number needed to treat. According to the study authors, 26 women would need to take exemestane for five years to prevent a single case of breast cancer. It should be noted, however, that few women in the study completed five years of therapy. Since this is being used as a preventive measure in healthy women, side effects are very important and data should have been provided. The story indicates that "slightly" more women taking exemastane experienced hot flashes, fatigue, sweating, insomnia, and joint pain, compared to those taking placebo pills. It would have been helpful to note, for example, that 40% in the exemestane group experienced a hot flash versus 32% in the placebo group. Citing older research, the story indicates that that joint pain, muscle aches, problems having sex, and vaginal dryness may be more evident with a longer duration of use. The story makes it clear that the study was a large-scale, placebo-controlled, randomized trial, which enrolled over 4500 women in North America and Europe. The women included had at least one risk factor for breast cancer. It also notes that given the significant risk reduction associated with exemestane, the study was stopped after 3 years to give women in the control arm the option of taking exemestane to prevent possible breast cancers. More information regarding participants' characteristics, including age and race would have been helpful. This story did not engage in disease-mongering. In addition to including experts not affiliated with the exemestane study, the story also notes that the it was funded by the Canadian Cancer Society, the Avon Foundation, and Pfizer. In addition, the writer points out that the study lead and a few other authors have received speaking fees from Pfizer and other pharmaceutical companies that make cancer drugs. This story compares the benefits and harms of exemestane with tamoxifen; however, a mention of how these compare with raloxifene, would have been useful. The availability of aromatase inhibitors is not in question. It's clear from the story that aromatase inhibitors are currently used to prevent breast cancer recurrences. It's also clear that this is the first study evaluating its utility for preventing the first instance of breast cancer in healthy women with a higher risk of developing the disease. The story does not appear to be based on the press release.

Answer: Hormone-blocking drug reduces breast cancer risk

Question: Cuomo's cautiously upbeat report at a daily briefing came as the daily death toll across the state, the epicenter of the pandemic in the United States, dropped to 540 on April 17, down from 630 a day earlier and the lowest in more than two weeks. The governor said total hospitalizations of patients being treated for COVID-19, the respiratory illness caused by the coronavirus, came to 16,967, a drop of more than 1,300 over the past three days. Intubations and admissions to intensive care units also continued on their downward trend. "If you look at the past three days, you could argue that we are past the plateau and we're starting to descend which would be very good news," Cuomo said. He said, however, that about 2,000 infected people were newly admitted to hospitals on Friday, which he characterized as "still an overwhelming number," and reiterated that he would take a cautious approach to reopening businesses and schools. Cuomo repeated a call for the federal government to help coordinate and provide funding for the mass testing that he and other governors have said is needed to determine when it is safe for people to go back to work. Providing new details on the challenge, Cuomo said a survey of labs in his state revealed an inability to procure the chemical reagents needed to run the tests on machines supplied by private manufacturers like Roche Holding AG. "They bought the machine, they have the machine, they have the test, but they need the reagents to do a higher volume of tests," Cuomo said, adding that makers like Roche are struggling to get the reagents from China. "That's the logjam we are in." New York disclosed 7,090 new positive cases over the last 24 hours for a total of 236,732 cases, while deaths increased by 540 to 13,362, marking by far the largest number of fatalities of any state. Even with stabilizing numbers, Cuomo said the pandemic was taking a severe emotional and economic toll on people, and estimated the impact on society would prove to be the biggest challenge facing the country since World War Two. "On every level this is a terrible experience, Cuomo said. "It is as tumultuous a time as we have ever seen."

Answer: New York Governor sounds optimistic note as coronavirus numbers improve.

Question: The story mentions that the Internet-based program is a "low-cost" option for treating insomnia; however, nothing more specific regarding cost is provided. It is presumed that the site will be proprietary; if so, what are the expected usage fees? The story states that compared to the control group, the treatment group woke up fewer times, spent fewer minutes awake, and had an improved score; however, the reader is not given any quantitative data or context to determine if these improvements are really meaningful in a person's life. The story does not mention any possible harms that may be associated with managing insomnia via an Internet-based program. For example, might people develop worsening insomnia because of reinforcement of bad habits? A comment regarding the lack of identifiable harms would have been sufficient. The story accurately described the methodology and the participants; although this could have been further improved by providing more information about the control group, namely, that they did receive any type of treatment for insomnia. Additionally, the story effectively conveyed that this was a small study with a fairly homogenous population. This story does not directly address the prevalence of insomnia, but the overall tone does not suggest disease-mongering. This story includes comments from two independent experts, as well as a study co-author. The writer also mentions that the study was funded by a grant from the National Institute of Mental Health. This story includes information on the benefits of cognitive behavioral therapy and working with a therapist for treating insomnia and briefly mentions sleep medications. The story states that this Internet-based program "could one day" be an option for treating insomnia, which suggests that it is not yet ready for prime time. The story conveyed that this is a novel treatment modality for insomnia. The story does not appear to rely on a press release and quotes multiple sources that appear to be from interviews.

Answer:
Internet-based therapy shows promise for insomnia